537 related articles for article (PubMed ID: 21074058)
1. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P; Hamid O; O'Day S
Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
[TBL] [Abstract][Full Text] [Related]
2. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
4. Management of immune-related adverse events and kinetics of response with ipilimumab.
Weber JS; Kähler KC; Hauschild A
J Clin Oncol; 2012 Jul; 30(21):2691-7. PubMed ID: 22614989
[TBL] [Abstract][Full Text] [Related]
5. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
[TBL] [Abstract][Full Text] [Related]
6. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.
Kähler KC; Hassel JC; Heinzerling L; Loquai C; Mössner R; Ugurel S; Zimmer L; Gutzmer R;
J Dtsch Dermatol Ges; 2016 Jul; 14(7):662-81. PubMed ID: 27373241
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
8. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
Camacho LH
Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
[TBL] [Abstract][Full Text] [Related]
9. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
Kähler KC; Hauschild A
J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab for advanced melanoma: a nursing perspective.
Ledezma B
Oncol Nurs Forum; 2009 Jan; 36(1):97-104. PubMed ID: 19136343
[TBL] [Abstract][Full Text] [Related]
11. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
Lotem M; Merims S; Frank S; Ospovat I; Peretz T
Harefuah; 2012 Oct; 151(10):585-8, 604. PubMed ID: 23316667
[TBL] [Abstract][Full Text] [Related]
12. [Antibody therapies for melanoma].
Kiniwa Y; Okuyama R
Nihon Rinsho; 2012 Dec; 70(12):2172-6. PubMed ID: 23259392
[TBL] [Abstract][Full Text] [Related]
13. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
Weber J
Oncologist; 2007 Jul; 12(7):864-72. PubMed ID: 17673617
[TBL] [Abstract][Full Text] [Related]
14. Anti-CTLA-4 antibody adjuvant therapy in melanoma.
Eggermont AM; Testori A; Maio M; Robert C
Semin Oncol; 2010 Oct; 37(5):455-9. PubMed ID: 21074060
[TBL] [Abstract][Full Text] [Related]
15. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
16. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.
Berman D; Parker SM; Siegel J; Chasalow SD; Weber J; Galbraith S; Targan SR; Wang HL
Cancer Immun; 2010 Nov; 10():11. PubMed ID: 21090563
[TBL] [Abstract][Full Text] [Related]
17. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.
Klein O; Ebert LM; Nicholaou T; Browning J; Russell SE; Zuber M; Jackson HM; Dimopoulos N; Tan BS; Hoos A; Luescher IF; Davis ID; Chen W; Cebon J
Clin Cancer Res; 2009 Apr; 15(7):2507-13. PubMed ID: 19318477
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
Bakacs T; Mehrishi JN; Moss RW
Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab: a promising immunotherapy for melanoma.
Thumar JR; Kluger HM
Oncology (Williston Park); 2010 Dec; 24(14):1280-8. PubMed ID: 21294471
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.
Wilgenhof S; Corthals J; Heirman C; van Baren N; Lucas S; Kvistborg P; Thielemans K; Neyns B
J Clin Oncol; 2016 Apr; 34(12):1330-8. PubMed ID: 26926680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]